Stem Cell Therapy for Hip Pain: What the Process Involves

Hip pain is one of the most functionally limiting forms of chronic joint pain. The hip joint bears the body’s full weight during standing, walking, and most daily activities, and when it degenerates or becomes inflamed, the consequences affect mobility, sleep, work capacity, and overall quality of life in ways that patients often describe as more disabling than they anticipated before the condition progressed. For many years, the primary treatment options for advanced hip disease were symptom management and eventual joint replacement. Regenerative medicine has introduced a biological alternative that research suggests may be appropriate for a subset of patients, particularly those with early to moderate hip osteoarthritis who want to avoid or delay surgical intervention.

This article explains the common sources of chronic hip pain, how regenerative therapy approaches the hip technically, what the recovery and functional improvement timeline looks like, and what candidacy for hip regenerative therapy involves.

Common Sources of Chronic Hip Pain

Hip Osteoarthritis: Mechanism and Progression

The hip joint is a ball-and-socket joint formed by the rounded head of the femur and the cup-shaped acetabulum of the pelvis. The articular surfaces of both the femoral head and the acetabular socket are covered with articular cartilage, which allows the joint surfaces to move smoothly during the enormous range of motion that the hip performs daily. As in the knee, this cartilage has no direct blood supply and limited intrinsic repair capacity.

Hip osteoarthritis develops when articular cartilage begins to degrade through a combination of mechanical wear, inflammatory signaling, and impaired repair biology. The result is progressive joint space narrowing visible on imaging, changes to the underlying subchondral bone, and reactive bone spur formation at the joint margins. The synovium becomes inflamed, contributing to pain and swelling within the joint capsule.

The pain pattern of hip osteoarthritis is important for diagnosis because it differs from other causes of hip-area pain. True hip joint pain typically presents in the groin, sometimes with referral to the anterior thigh or toward the knee. Patients often describe it as a deep aching or an activity-related pain that worsens with weight-bearing and improves with rest. This groin presentation is distinct from the lateral hip pain of greater trochanteric pain syndrome, the buttock pain of sacroiliac joint dysfunction, and the referred pain patterns from lumbar spine pathology.

Hip osteoarthritis affects a significant proportion of older adults, with prevalence estimates suggesting that symptomatic hip OA affects approximately 10 percent of adults over 55. Its progression rate varies considerably among individuals, with some patients experiencing rapid joint space loss over years and others maintaining stable disease for extended periods.

Labral and Soft Tissue Involvement

The acetabular labrum is a ring of fibrocartilage that deepens the socket of the hip joint and contributes to joint stability, fluid distribution within the joint, and proprioception. Labral tears occur through several mechanisms, including femoroacetabular impingement (FAI), repetitive rotational loading in athletes, and degenerative changes associated with aging.

FAI is a condition in which abnormal bony anatomy, either a bump on the femoral head (cam impingement), a deep or overhanging acetabular rim (pincer impingement), or both, creates abnormal contact within the hip joint during movement. This contact damages the labrum over time and, once the labrum is injured, may accelerate cartilage damage in the affected region. The connection between labral health and joint health is well-established, and in younger patients with isolated labral tears, surgical labral repair is often the appropriate initial treatment. In older patients where labral pathology co-exists with osteoarthritis, the clinical picture is more complex.

Other soft tissue sources of hip-area pain include iliopsoas tendinopathy, in which the large hip flexor tendon that passes over the front of the hip joint becomes irritated or degenerative, greater trochanteric pain syndrome, in which the tendons and bursa at the lateral hip become inflamed, and IT band syndrome, in which tightness in the iliotibial band contributes to lateral hip and thigh pain. Some of these soft tissue conditions may respond to targeted regenerative injections, while others require different approaches. The clinical assessment determines which structures are contributing to the patient’s symptom picture.

Why Hip Pain Is Often Undertreated

Several factors contribute to hip pain being less promptly or adequately addressed compared to knee pain. First, the location of hip joint pain in the groin can be confusing. Patients and sometimes non-specialist clinicians initially attribute groin pain to other causes, delaying recognition of hip joint involvement. Some patients with hip OA are initially evaluated and treated for lumbar spine conditions because of referral pain patterns, and they do not receive appropriate hip-focused assessment until considerably later.

Second, many patients are not aware of the existence of hip OA or that it can progress to a degree of functional limitation comparable to knee OA. Hip replacement is widely known as a surgical option, and many patients believe that this is the only meaningful intervention beyond conservative symptom management. The space between NSAIDs and joint replacement is often not presented to patients as containing legitimate options, which leaves regenerative approaches underdiscussed until the patient discovers them independently.

Third, hip pain often develops and progresses gradually enough that patients adapt their activity levels and lifestyle incrementally, sometimes not recognizing how significant their functional limitation has become until they attempt to resume a previous activity or compare their current mobility to what it was years earlier.

How Regenerative Therapy Approaches the Hip

Intra-Articular Injection and Imaging Guidance

The primary delivery method for stem cell therapy in hip osteoarthritis is intra-articular injection into the femoroacetabular joint space. Placing the therapeutic agent within the joint space allows the cells to interact with the articular cartilage surfaces, the synovial membrane, and the joint fluid environment where the biological effects of regenerative therapy are most relevant.

The hip joint is a significantly deeper structure than the knee. Its depth from the skin surface varies considerably based on patient body habitus, ranging from approximately four to ten centimeters in many adults. This depth, combined with the surrounding anatomy that includes major blood vessels and the variable geometry of the femoral head and acetabulum, makes accurate delivery substantially more technically demanding than knee injection. Imaging guidance for hip injection is not optional in responsible clinical practice, and the choice of imaging modality affects the accuracy of delivery.

The anterior approach to the hip joint is most commonly used for intra-articular injection, with the needle advanced from the front of the thigh toward the joint space between the femoral head and acetabular rim. The lateral approach is used in some clinical situations depending on anatomy and physician training. In either case, the needle must be confirmed to be within the joint capsule before the therapeutic agent is delivered.

Why the Hip Requires Fluoroscopy in Many Cases

The depth and anatomy of the hip joint make fluoroscopy the standard imaging guidance for hip intra-articular injection in many clinical situations. Fluoroscopy provides real-time bone visualization that allows the physician to track needle position relative to the femoral head and acetabular rim throughout the procedure, then confirm intra-articular placement by injecting contrast and observing its spread within the joint space.

The femoral vessels, including the femoral artery and femoral vein, pass in close proximity to the hip joint along the anterior thigh. Accurate needle guidance under imaging reduces the risk of inadvertent vascular contact during needle advancement.

Ultrasound can successfully guide hip injections in some patients, particularly those with lower body habitus and accessible joint anatomy. Studies examining ultrasound-guided hip injections in controlled populations have found accuracy rates approaching 100 percent when performed by experienced operators with appropriate technique. However, ultrasound becomes progressively more challenging as depth and tissue complexity increase, and fluoroscopic guidance with contrast confirmation provides the most reliable documentation of intra-articular placement across the broadest range of patients.

The practical implication for patients is that hip regenerative procedures require either a fluoroscopy-capable suite or an experienced ultrasound-guided injector who has specifically trained in hip access, not just a general ultrasound machine available in a clinic that primarily treats more superficial structures. Patients should ask specifically about what imaging will be used for their hip procedure and confirm that the physician has specific training and volume in hip joint injection under that imaging modality.

What Cells Are Typically Used

For hip osteoarthritis, autologous cell sources include mesenchymal stem cells derived from bone marrow aspirate concentrate and from adipose (fat) tissue. Both have been studied in the hip OA literature, with the 2024 scoping review published in HSS Journal examining bone marrow-derived MSC therapy for hip OA specifically, and the European Journal of Orthopaedic Surgery systematic review including studies using both bone marrow and adipose-derived sources.

In practice, the choice between bone marrow and adipose tissue as the cell source reflects both physician training and preference and patient-specific factors including tissue availability, yield considerations, and prior procedures. Platelet-rich plasma is often co-administered with stem cells or sequenced as a preparatory or follow-up intervention. PRP provides growth factors that may support the local tissue environment for incoming stem cells and may extend the duration of the biological response.

Volume injected intra-articularly for hip procedures is typically in the range of 3 to 5 milliliters, though this varies with the physician’s protocol and the concentration of the cell preparation. As with knee procedures, optimal dosing protocols for hip injection are still under clinical investigation, and no universal standard currently exists.

Recovery and Activity Expectations

Post-Procedure Restrictions for the Hip

The recovery protocol following hip stem cell injection generally involves a period of reduced weight-bearing and activity restriction designed to protect the treated joint while the biological response develops. Most patients are advised to limit weight-bearing on the treated hip for the first 24 to 48 hours following the procedure. During this period, modified ambulation with minimal weight transfer through the treated hip is typical, though most patients do not require crutches for more than a very short period.

After the initial 48-hour period, walking as tolerated is generally encouraged. Gentle, regular movement supports joint circulation, maintains range of motion, and contributes to the tissue remodeling environment. The goal during recovery is to maintain appropriate activity without placing high-impact or high-torque stress on the healing joint.

High-impact activities including running, jumping, and sports involving significant hip loading are typically restricted for six to eight weeks following the procedure. Activities involving significant hip rotation under load, such as golf swings and tennis groundstrokes, are also restricted during this period. The rationale is that high mechanical stress during the early cellular activity window may disrupt the biological processes the treatment is intended to support.

Most physicians advise against NSAID use during the recovery period for the same reason as in knee procedures. The inflammatory signaling that NSAIDs suppress is part of the biological cascade that regenerative therapy depends on, and suppressing it during the active recovery window may reduce the effectiveness of the treatment. Acetaminophen and ice application for discomfort management during the first week are typically appropriate, and patients should follow their physician’s specific post-procedure guidelines.

Physical therapy typically begins approximately six weeks after the procedure in patients who are showing an appropriate recovery trajectory. Rehabilitation focuses on restoring hip range of motion, strengthening the muscles that support and stabilize the hip joint, and correcting any movement patterns that may be contributing to abnormal joint loading. Physical therapy integrated with regenerative treatment is associated with better functional outcomes than either intervention alone in many cases.

When to Expect Functional Improvement

Patients with hip osteoarthritis who receive stem cell therapy often report their first noticeable functional changes in the range of six to ten weeks following the procedure. The patterns of initial improvement in hip cases are similar to those observed in knee cases: stiffness reduction tends to be noticed before pain score changes, and improvements in walking tolerance, particularly in distance walked before onset of hip discomfort, are commonly among the early functional improvements patients report.

At the three-month follow-up, the physician assesses pain scores, functional outcome measures, and hip range of motion against the baseline assessment. Some patients show clear, meaningful improvement at three months. Others are still progressing through an improvement trajectory that will continue to six or twelve months. The treating physician interprets the three-month data in the context of the individual patient’s presentation and expected response pattern.

Published research on hip regenerative therapy outcome timelines includes a 2023 narrative review finding that five of six studies reported statistically significant improvement in patient-reported outcomes following MSC injections, with positive radiological findings in the two studies that reported imaging data. A 2024 European systematic review encompassing 10 studies and 316 patients found generally positive findings for pain scores and functional improvements, though the authors noted that study quality and methodology varied considerably across the included literature.

The current evidence base for hip regenerative therapy is earlier-stage than the knee evidence base, reflecting the fact that hip OA has been studied less extensively in regenerative medicine trials and that the technical demands of hip injection have limited the number of centers that have accumulated meaningful case series. Patients considering hip regenerative therapy should understand this distinction in evidence maturity relative to knee applications.

Candidacy for Hip Regenerative Therapy

Hip OA Grade and What It Means for Regenerative Candidacy

The Kellgren-Lawrence grading system applies to hip OA as it does to knee OA, assessing joint space narrowing, osteophyte formation, and bone changes on plain radiographs from grade 1 through grade 4. The candidacy principles are parallel: KL Grades 1 through 3 represent the range where regenerative therapy has the most rational biological basis and where available clinical evidence is most supportive.

Within this range, the physician uses both X-ray grading and MRI cartilage assessment to determine candidacy more precisely. Plain X-rays provide information about joint space, bony changes, and overall structural alignment. MRI provides information about the actual thickness and integrity of the articular cartilage, the status of the labrum, the presence of bone marrow edema, and soft tissue changes that plain X-ray does not capture. A patient who grades as KL 3 on X-ray may have significantly different residual cartilage on MRI assessment, with the imaging detail affecting the candidacy determination in a meaningful way.

Symptom severity and its relationship to structural findings also informs candidacy. A patient with KL Grade 2 changes and significant functional limitation who has exhausted conservative care represents a different clinical picture than one with KL Grade 3 changes who is still managing well with conservative measures. The physician integrates structural findings, functional impact, prior treatment history, and patient goals to arrive at a candidacy determination that is specific to the individual.

Advanced Hip Degeneration: When Surgical Assessment Cannot Be Deferred

Kellgren-Lawrence Grade 4 hip OA, characterized by loss of joint space and bone-on-bone contact, represents the structural limit for regenerative therapy applied to the joint. The clinical reasoning is the same as for the knee: when articular cartilage has been largely or completely lost, the tissue substrate that regenerative therapy’s biological mechanisms work with is not present. Injecting cells into a joint with no remaining cartilage does not address the structural situation in a meaningful way.

For patients presenting with grade 4 hip OA, severe functional limitation from joint degeneration, multiple prior failed interventions, or a pattern of rapid joint space loss on serial imaging, honest clinical practice requires that total hip arthroplasty be part of the conversation. Total hip replacement is one of the most successful elective surgical procedures performed in the United States, with well-established outcomes and a large evidence base. For appropriate patients, it represents the most reliable path to sustained pain relief and functional restoration.

A regenerative medicine physician who evaluates a hip OA patient and determines that surgical consultation is the appropriate recommendation is serving that patient’s interests, not failing them. The willingness to make referrals when referrals are appropriate is a reflection of clinical integrity. Patients whose conditions exceed what regenerative therapy can meaningfully address deserve an honest conversation about this, with clear explanation of why surgery is being recommended and what that referral pathway looks like, rather than a treatment proposal that does not align with the severity of their condition.

This approach to hip cases includes this honest candidacy assessment. When a patient’s hip degeneration exceeds the clinical scope of regenerative therapy, the appropriate next step is identifying the right surgical consultation, not offering a procedure that is unlikely to match the patient’s needs.

Sources

Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. This content is not a substitute for consultation with a qualified, licensed healthcare provider. Regenerative medicine procedures vary in outcomes based on individual health status, condition severity, and other clinical factors. No specific results are guaranteed. Consult a board-certified physician to determine whether any treatment discussed here is appropriate for your situation.